Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 1.00 |
| ▸ | MAOB | P27338 | 5/20 | 1.00 |
| ▸ | ACHE | P22303 | 2/20 | 1.00 |
| ▸ | BACE1 | P56817 | 1/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30019972 | 0.99 | MAOA (0.97) | MAOAMAOBACHEBACE1BCHE | |
| SCHEMBL620669 | 0.87 | MAOA (1.00) | MAOAMAOBACHEBACE1BCHE | |
| SCHEMBL2519896 | 0.86 | MAOA (0.76) | MAOAMAOBACHEBACE1BCHE | |
| Hydrochloric Acid SCHEMBL620552 | 0.86 | MAOA (0.98) | MAOAMAOBACHEBACE1BCHE | |
| Hydrochloric Acid SCHEMBL621934 | 0.86 | MAOA (0.98) | MAOAMAOBACHEBACE1BCHE | |
| SCHEMBL621285 | 0.85 | MAOA (1.00) | MAOAMAOBACHEBACE1BCHE | |
| Hydrochloric Acid SCHEMBL621870 | 0.84 | MAOA (0.98) | MAOAMAOBACHEBACE1BCHE | |
| Hydrochloric Acid SCHEMBL623315 | 0.84 | MAOA (0.98) | MAOAMAOBACHEBACE1BCHE | |
| SCHEMBL10156171 | 0.82 | MAOA (1.00) | MAOAMAOBACHEBACE1BCHE | |
| SCHEMBL620567 | 0.81 | MAOA (0.68) | MAOAMAOBACHEBACE1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182566-A1 | Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-06-06 | — | — | US | disclosed |
| US-11884728-B2 | Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-01-30 | — | — | US | disclosed |
| US-11884727-B2 | Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-01-30 | — | — | US | disclosed |
| EP-4269439-A2 | REDUCING SYSTEMIC REGULATORY T CELL LEVELS OR ACTIVITY FOR TREATMENT OF DISEASE AND INJURY OF THE CNS | Yeda Research and Development Co. Ltd (IL) | 2023-11-01 | — | — | EP | disclosed |
| CN-116492457-A | Lowering systemic regulatory T cell levels or activity for treatment of diseases and injuries of the central nervous system | 耶达研究与开发有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-108348607-B | Lowering systemic regulatory T cell levels or activity for treatment of diseases and injuries of the central nervous system | 耶达研究与开发有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230183350-A1 | Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-06-15 | — | — | US | disclosed |
| US-11643464-B2 | Reducing systemic regulatory T cell levels or activity for treatment of a retinal degeneration disorder | Yeda Research and Develpment & Co. Ltd (IL) | 2023-05-09 | — | — | US | disclosed |
| US-11492405-B2 | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the CNS | YEDA RESEARCH AND DEVELOPMENT CO. LTD (IL) | 2022-11-08 | — | — | US | disclosed |
| CN-114081946-A | Treatment of CNS diseases and injuries by reducing the level or activity of systemic regulatory T cells | 耶达研究与开发有限公司 | 2022-02-25 | — | — | CN | disclosed |
| WO-2012020389-A1 | NEUROPROTECTIVE AND NEURO-RESTORATIVE IRON CHELATORS AND MONOAMINE OXIDASE INHIBITORS AND USES THEREOF | VARINEL INC (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012020389-A1 | NEUROPROTECTIVE AND NEURO-RESTORATIVE IRON CHELATORS AND MONOAMINE OXIDASE INHIBITORS AND USES THEREOF | VARINEL INC (US) | 2012-02-16 | — | — | WO | disclosed |
| US-8058442-B2 | Neuroprotective iron chelators and pharmaceutical compositions comprising them | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2011-11-15 | — | — | US | disclosed |
| US-8058442-B2 | Neuroprotective iron chelators and pharmaceutical compositions comprising them | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2011-11-15 | — | — | US | disclosed |
| WO-2010086860-A2 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2010-08-05 | — | — | WO | disclosed |
| US-20100152108-A1 | METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE | MEDIVATION NEUROLOGY, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| CN-101631547-A | Combination therapy for the treatment of alzheimer's disease using delmopine and donepezil | MEDIVATION INC | 2010-01-20 | — | — | CN | disclosed |
| WO-2009135091-A1 | USE OF ASENAPINE AND RELATED COMPOUNDS FOR THE TREATMENT OF NEURONAL OR NON-NEURONAL DISEASES OR CONDITIONS | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| EP-2086538-A2 | COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING I.A. DIMEBON AND DOLEPEZIL | Medivation Neurology, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008051599-A2 | COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING I. A. DIMEBON AND DOLEPEZIL | MEDIVATION NEUROLOGY, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183350-A1 | Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS | CD4, NFATC1, TSLP | MAOA 1947/4885MAOB 1074/4885ACHE 621/4885 |
| US-20240182566-A1 | Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS | CD4, PMP22, GMFG | MAOA 2905/4885MAOB 1846/4885ACHE 631/4885 |
| US-20100152108-A1 | METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE | PSEN2, APP, PSEN1 | MAOA 67/4885MAOB 14/4885ACHE 12/4885 |
| US-11884727-B2 | Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis | IL2, PMP22, TSLP | MAOA 3224/4885MAOB 2318/4885ACHE 496/4885 |
| US-11643464-B2 | Reducing systemic regulatory T cell levels or activity for treatment of a retinal degeneration disorder | ALDH1A2, RBP4, RBP1 | MAOA 2906/4885MAOB 1768/4885ACHE 2228/4885 |
| US-11492405-B2 | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the CNS | CD4, NFATC1, TSLP | MAOA 1947/4885MAOB 1074/4885ACHE 621/4885 |
| US-11884728-B2 | Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis | IL2, PMP22, TSLP | MAOA 3321/4885MAOB 2423/4885ACHE 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.